滤泡性腺瘤中检出TERT、HRAS与EIF1AX突变一例
68岁女性甲状腺结节患者,细胞学意义不明的异型性,细针穿刺二代测序检出TERT C228T、HRAS Q61R及EIF1AX A113_splice突变,右甲状腺叶切除后病理为滤泡性腺瘤,三种突变在手术标本中均被检出。作者报告此罕见病例并认为TERT启动子突变可能是滤泡性甲状腺癌分子发病机制的早期遗传事件。
要点
- 滤泡性腺瘤可同时携带TERT启动子、HRAS及EIF1AX突变。
- 细针穿刺检出的三种突变在最终手术标本中均被证实。
- 作者认为TERT启动子突变可能是滤泡性甲状腺癌的早期遗传事件。
核心结论
- 作者报告一例滤泡性腺瘤患者同时携带TERT、HRAS和EIF1AX突变的罕见病例。
- 作者认为TERT启动子突变可能是滤泡性甲状腺癌分子发病机制的早期遗传事件。
研究设计与样本
- 病例报告:68岁女性,甲状腺功能减退,右甲状腺结节,细胞学为意义不明的异型性。
- 对结节细针穿刺标本行二代测序,并行右甲状腺叶切除术,最终病理为滤泡性腺瘤。
主要发现
- 细针穿刺标本检出TERT基因C228T突变、HRAS基因Q61R突变及EIF1AX基因A113_splice突变。
- 右甲状腺叶切除后最终病理为滤泡性腺瘤。
- 原细针穿刺标本中检出的三种突变在最终手术标本中均被检出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular markers are increasingly used as diagnostic tools in the management of thyroid nodules. There is a paucity of studies evaluating the prevalence of molecular markers in benign lesions. PATIENT FINDINGS: A 68-year-old woman with hypothyroidism presented with a right thyroid nodule, which was atypia of undetermined significance on cytology. The fine-needle aspirate of the nodule was examined with next-generation sequencing and found to harbor a C228T mutation in the TERT gene, a Q61R mutation in the HRAS gene, and an A113_splice mutation in the EIF1AX gene. Right thyroid lobectomy was performed, with final pathology showing follicular adenoma. All three mutations detected in the original fine-needle aspirate specimen were detected in the final surgical specimen as well. CONCLUSIONS: A rare case of TERT, HRAS, and EIF1AX mutations is reported in a patient with follicular adenoma. TERT promoter mutations may be an early genetic event in the molecular pathogenesis of follicular thyroid carcinoma.
引用
- Topf MC, Wang ZX, Tuluc M, et al. TERT, HRAS, and EIF1AX Mutations in a Patient with Follicular Adenoma. Thyroid. 2018. PMID: 29669480. doi:10.1089/thy.2017.0504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。